This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Niall Mackenzie, DPM, MA; Wendy M. Holton
London, England

JAMA. 1991;265(1):26.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.—

Freeman et al¹, in their article "Ineffectiveness of Progesterone Suppository Treatment for Premenstrual Syndrome," state that the symptoms were not significantly improved by progesterone compared with placebo.

Dalton² has shown that, in 1096 patients, only 23% responded to a dose as low as 400 mg daily, 33% responded to a dose of 400 mg twice daily, and another 20% responded to 400 mg three times daily, with 46% of the sample requiring a dose higher than 400 mg of progesterone twice daily. Maddock et al³ noted the variation of content of the progesterone suppositories. When 14 different types of progesterone suppositories from the United States were analyzed, only one was within the 3% limit required by the Committee of Safety in Medicines in Britain, and six ranged between 57% and 34% of the stated content.

Freeman et al make no mention of the patient's . . . [Full Text PDF of this Article]

Footnotes
Edited by Drummond Rennie, MD, Deputy Editor (West), and Don Riesenberg, MD, Senior Editor.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?